

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM***(to be used for all correspondence after initial filing)*

| | |
|------------------------|---------------------|
| Application Number | 10/522,660 |
| Filing Date | August 16, 2005 |
| First Named Inventor | Rentzeperis et al. |
| Art Unit | 1743 |
| Examiner Name | Landsman, Robert S. |
| Attorney Docket Number | 30923-713.831 |


Total Number of Pages in This Submission

10 + references


ENCLOSURES (Check all that apply)

| | | |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) <input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Forms 08A and B references |
| Remarks | | |

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

| | | | |
|--------------|---|----------|--------|
| Firm Name | WILSON SONSINI GOODRICH & ROSATI | | |
| Signature |  | | |
| Printed Name | Samir Elamrani, Ph.D. | | |
| Date | December 9, 2005 | Reg. No. | 43,601 |

CERTIFICATE OF MAILING

| | | | |
|---|---|------|------------------|
| I hereby certify that this paper is being E-filed to Mail Stop IDS, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. | | | |
| Signature |  | | |
| Typed or printed name | Ann Lygas | Date | December 9, 2005 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

☐ 37 CFR §1.97(b). This Information Disclosure Statement should be considered by the Office because:

- ☐ (1) It is being filed within 3 months of the application filing date of a national application and is other than a continued prosecution application under §1.53(d);
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage as set forth in §1.491 in an international application;
-- OR --
- ☒ (3) It is being filed before the mailing date of the first Office Action on the merits;
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under §1.114.

☐ 37 CFR §1.97(c). Although this Information Disclosure Statement is being filed after the period specified in 37 CFR §1.97(b), above, it is filed before the mailing date of the earlier of (1) a final office action under §1.113, (2) a notice of allowance under §1.311, or (3) an action that otherwise closes prosecution on the merits, this Information Disclosure Statement should be considered because it is accompanied by one of:

- ☐ a certification as specified in §1.97(e) provided concurrently herewith;
-- OR --
- ☐ a fee of \$180.00 as set forth in §1.17(p) authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 CFR §1.97(d). Although this Information Disclosure Statement is being filed after the mailing date of the earlier of (1) a final office action under §1.113 or (2) a notice of allowance under §1.311, it is being filed before payment of the issue fee and should be considered because it is accompanied by:

- A. a certification as specified in §1.97(e); and
- B. a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this Statement.

☐ 37 CFR §1.97(e). A certification signed by an Attorney of Record is provided herewith as required under 37 CFR §§1.97(b) and (c).

☒ 37 CFR §1.98(a)(2). The content of the Information Disclosure Statement is as follows:

- ☐ Copies of each of the references listed on the attached Form PTO/SB/08A are enclosed herewith.
-- OR --
- ☒ Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08A are NOT enclosed.
-- AND/OR --
- ☒ Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08A are enclosed in accordance with 37 CFR §1.98(a)(2).
-- AND/OR --
- ☐ Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98(a)(2)(iii).

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Rentzeperis et al.

Serial Number: 10/522,660

Filing Date: August 16, 2005

Title: Method for the Identification of Ligands

Group Art Unit: 1743

Examiner: Robert S. Landsman


CONFIRMATION NO: 8712

Certificate of Mailing 37 CFR §1.8

I hereby certify that this paper is being E-filed to Mail Stop IDS, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450

On December 9, 2005

Signature



Printed Name

Ann Lygas

Mail Stop IDS
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached forms PTO/SB/08A. A copy of each listed publication is being submitted, if required, pursuant to 37 C.F.R. §§1.97-1.98, as indicated below.

Applicants respectfully requests that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached forms PTO/SB/08 in accordance with MPEP §609.

Applicants reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

- ☐ 37 CFR §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or references.
- ☐ Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.
- ☐ Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation of the non-English language reference(s) is provided herewith
- ☒ Attached is a copy of the EP search report(s) from a corresponding patent application(s).
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No.30923-713.831)

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: December 9, 2005

By: Samir Elamrani
Samir Elamrani, Ph.D.
Reg.No. 43,601

650 Page Mill Road
Palo Alto, CA 94304-1050
(650) 493-9300
Customer No. 021971

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/522,660 |
| | | | | Filing Date | August 16, 2005 |
| | | | | First Named Inventor | Rentzeperis et al. |
| | | | | Art Unit | 1743 |
| | | | | Examiner Name | Landsman, Robert S. |
| Sheet | 1 | of | 2 | Attorney Docket Number | 30923-713.831 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| /RL/ | 1 | US-2002-048811 | 04-25-2002 | Devreotes et al. | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|---|--------------------------------|--|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| /RL/ | 2 | WO-02-103321 | 12-27-2002 | Anadys Pharmaceuticals, Inc. | | |
| /RL/ | 3 | WO-99-27365 | 06-03-1999 | Tularik Inc. | | |
| /RL/ | 4 | WO-97-42500 | 11-13-1997 | 3- Dimensional Pharmaceuticals, Inc. | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|-----------------------|-------------------|--------------------|------------|
| Examiner Signature | /Robert Landsman/ | Date Considered | 03/19/2008 |
|-----------------------|-------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | | | |
|--|---|---------------------|---|--------------------------|--|--------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | | |
| | | | | Application Number | | 10/522,660 |
| | | | | Filing Date | | August 16, 2005 |
| | | | | First Named Inventor | | Rentzeperis et al. |
| | | | | Art Unit | | 1743 |
| Examiner Name | | Landsman, Robert S. | | | | |
| Sheet | 2 | of | 2 | Attorney Docket Number | | 30923-713.831 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /RL/ | 5 | GREENFIELD et al., "Increase in the Stability and Helical Content of Estrogen Receptor alpha in the Presence of the Estrogen Response Element: Analysis by Circular Dichroism Spectroscopy," Biochemistry 2001, 40, 6646-6652 | |
| /RL/ | 6 | ZHANG, Y. and ZHANG, Z., "Low-Affinity Binding Determined by Titration Calorimetry Using a High-Affinity Coupling Ligand: A Thermodynamic Study of Ligand Binding to Protein Tyrosine Phosphatase 1B ¹ (1998) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Examiner signature | /Robert Landsman/ | | Date Considered 03/19/2008 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



P.B.5818 - Patentlaan 2
2260 HV Rijswijk (ZH)
☎ (070) 3 40 20 40
FAX (070) 3 40 30 16

Europäisches
Patentamt

European
Patent Office


Office européen
des brevets

Generaldirektion 1

Directorate General 1

Direction générale 1

Vossius & Partner
Siebertstrasse 4
81675 München
ALLEMAGNE



EPO Customer Services

Tel.: +31 (0)70 340 45 00

Date

04.10.05

Reference
K3087 EP S3

Application No./Patent No.
02766306.1 - 2404 PCT/US0229661

Applicant/Proprietor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

COMMUNICATION

The European Patent Office herewith transmits as an enclosure the supplementary European search report under Article 157(2)(a) EPC for the above-mentioned European patent application.

If applicable, copies of the documents cited in the European search report are attached.

- ☒ Additional set(s) of copies of the documents cited in the European search report is (are) enclosed as well.

Refund of the search fee

If applicable under Article 10 Rules relating to fees, a separate communication from the Receiving Section on the refund of the search fee will be sent later.





| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|---|--|---|---|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int.Cl.7) |
| Y | WO 97/42500 A (3-DIMENSIONAL PHARMACEUTICALS, INC) ✓ 13 November 1997 (1997-11-13) * the whole document * | 2-4, 9-11, 16-18, 20-22, 24-26, 28-30, 36, 39, 40 | G01N33/53 G01N33/567 A61K38/00 C07K1/00 C07K2/00 C07K4/00 C07K5/00 C07K7/00 C07K14/00 C07K16/00 C07K17/00 |
| Y | US 2002/048811 A1 (DEVREOTES PETER N ET AL) 25 April 2002 (2002-04-25) ✓ * the whole document * | 2-4, 9-11, 16-18, 20-22, 24-26, 28-30, 36, 39, 40 | |
| X | GREENFIELD N ET AL: "Increase in the Stability and Helical Content of Estrogen Receptor alpha in the Presence of the Estrogen Response Element: Analysis by Circular Dichroism Spectroscopy" BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 40, no. 22, 10 May 2001 (2001-05-10), pages 6646-6652, XP002980344 ✓ ISSN: 0006-2960 | 1,5-8, 12-15, 19,23, 27, 31-34,37 | TECHNICAL FIELDS SEARCHED (Int.Cl.7) G01N A61K C07K |
| Y | * the whole document * | 2-4, 9-11, 16-18, 20-22, 24-26, 28-30, 36, 39, 40 | |
| ----- -/- | | | |
| The supplementary search report has been based on the last set of claims valid and available at the start of the search. | | | |
| Place of search Munich | | Date of completion of the search 22 September 2005 | Examiner Diez Schlereth, D |
| CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document | | | |

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 76 6306

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

22-09-2005

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|----|---------------------|----------------------------|---------------------|
| WO 9742500 | A | 13-11-1997 | AU 741049 B2 | 22-11-2001 |
| | | | AU 3205097 A | 26-11-1997 |
| | | | CA 2253587 A1 | 13-11-1997 |
| | | | EP 0914608 A1 | 12-05-1999 |
| | | | HU 9902418 A2 | 29-11-1999 |
| | | | JP 2000511629 T | 05-09-2000 |
| | | | KR 2000011069 A | 25-02-2000 |
| | | | NZ 332754 A | 28-07-2000 |
| US 2002048811 | A1 | 25-04-2002 | AU 1323402 A | 29-04-2002 |
| | | | WO 0233102 A1 | 25-04-2002 |
| WO 9927365 | A | 03-06-1999 | AU 734875 B2 | 21-06-2001 |
| | | | AU 1598999 A | 15-06-1999 |
| | | | CA 2309879 A1 | 03-06-1999 |
| | | | EP 1032834 A1 | 06-09-2000 |
| | | | JP 3584211 B2 | 04-11-2004 |
| | | | JP 2001524672 T | 04-12-2001 |
| WO 02103321 | A | 27-12-2002 | CA 2450641 A1 | 27-12-2002 |
| | | | EP 1409982 A2 | 21-04-2004 |
| | | | JP 2004537047 T | 09-12-2004 |